조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C13H12F2N6O
CAS 번호:
Molecular Weight:
306.27
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI key
RFHAOTPXVQNOHP-UHFFFAOYSA-N
SMILES string
FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
grade
pharmaceutical primary standard
API family
fluconazole
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
유사한 제품을 찾으십니까? 방문 제품 비교 안내
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Biochem/physiol Actions
Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.
Fluconazole is an antifungal agent; highly selctive inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Potent inhibitor of CYP2C9. Interferes with fungal ergosterol synthesis; downregulates metallothionein gene.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Kim C M van der Elst et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1527-1533 (2014-08-26)
Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. Although timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended. We conducted a retrospective study of critically ill children treated
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
Jenny Wan Sai Cheong et al.
Medical mycology, 51(3), 261-269 (2012-09-20)
With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not
Daniel K Benjamin et al.
JAMA, 311(17), 1742-1749 (2014-05-06)
Invasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect on mortality and the safety of fluconazole are unknown. To evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.